Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the FDA. The meeting was related to TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC2).

Tonix Pharmaceuticals To Start Mid-Stage Long COVID Trial In Q4

The shares of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased by over 20% pre-market. This is why it happened.

Tonix Pharmaceuticals Shares Increase Over 20% Pre-Market: Why It Happened

Company Plans to Submit an IND to Support a Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)

AMC Entertainment

GameStop

Monday's coronavirus vaccine news was a real shot in the arm for the trio.

Why Meme Stocks AMC, GameStop, and Tonix Rocketed Higher Today

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased 10.84%. This is why it happened.

TNXP Stock Price Increased 10.84%: Why It Happened

Central Nervous System Pipeline Progressing with Two Phase 2 Studies (TNX-1300 and TNX-1900) and One Phase 3 Study (TNX-102 SL) Expected to Start This Year

Tonix Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Highlights

Robinhood

The small drugmaker is moving forward after disappointing clinical results.

What's Next for Robinhood Favorite Tonix Pharmaceuticals?

Investors seem cautiously optimistic about a new company facility in Massachusetts.

Why Tonix Pharmaceuticals Holding Is Rising Today

The ADC is Expected to Accelerate Development and Clinical Manufacturing of Vaccines, Including Vaccines for COVID-19, When Fully Operational The ADC is Expected to Accelerate Development and Clinical Manufacturing of Vaccines, Including Vaccines for COVID-19, When Fully Operational

Tonix Pharmaceuticals Announces Groundbreaking Ceremony for Massachusetts R&D Facility to House the Advanced Development Center (ADC) for Vaccine Programs

Is There Any Hope for Tonix Pharmaceuticals Stock?

R&D Facility in Frederick, MD is Expected to Provide Internal Capacity to Discover and Develop Vaccines and Antiviral Drugs Against COVID-19, its Variants and Other Infectious Diseases

Tonix Pharmaceuticals Announces Agreement to Acquire Infectious Disease R&D Facility to Accelerate Development of Vaccines and Antiviral Drugs

The company is stopping enrollment in a late-stage study for its lead pipeline candidate.

Why Tonix Pharmaceuticals Stock Is Crashing Today

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) fell by over 30% pre-market. This is why it happened.

TNXP Stock Falls Over 30% Pre-Market: Why It Happened

Following an unblinded, pre-planned interim analysis by the Independent Data Monitoring Committee (IDMC), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) will stop enrollment in the Phase 3 RALLY study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for fibromyalgia. The IDMC recommended stopping the trial for futility as TNX-102 SL is unlikely to demonstrate a statistically significant improvement in overall change from baseline in pain (primary endpoint) compared to placebo.

IDMC Recommends Tonix Pharma To Stop Enrollment In Fibromyalgia Trial; Shares Drop

The stock price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) fell 2.97% today. This is why it happened.

TNXP Stock Fell 2.97%: Why It Happened

RALLY Study Will Stop Enrolling New Participants Following Recommendation from an Interim Analysis Indicating Inadequate Separation from Placebo at Week-14 in the First 50% of Participants, Based on the Original Targeted Study Size

Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia

Barnwell Industries

Hut 8 Mining Corp

iBio

Ring Energy

Ur-Energy

W&T Offshore

Trending penny stocks can be a great addition to your watchlist, here's 7 popular small-caps for your list The post Popular Penny Stocks to Buy Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Popular Penny Stocks to Buy Right Now? 7 For Your Watchlist

Ambev

Auddia

Zomedica

Evofem Biosciences Inc

Luokung Technology Corp

Tellurian

Exela Technologies

Making a penny stocks watchlist for July? Check these 8 out The post Penny Stocks To Buy in 2021?

Penny Stocks To Buy in 2021? Check These 8 Out Next Month

Marin Software

Safe Bulkers

United States Antimony

Arbutus Biopharma

Ashford Hospitality Trust

Senseonics Holdings

Are these hot penny stocks on your morning watchlist? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 7 Small-Caps For Your Morning List

CHATHAM, N.J., June 28, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tonix was added to the broad-market Russell 3000® index and the small-cap Russell 2000® Index, effective after the U.S. market opens today, June 28, 2021, as part of the annual reconstitution of the Russell stock indexes.

Tonix Pharmaceuticals Added to Russell 2000® and Russell 3000® Indexes

The stock price of Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) increased 8.18% yesterday. This is why it happened.

TNXP Stock Price Increased 8.18%: Why It Happened

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) said in a regulatory filing that plans are underway to construct a commercial-scale manufacturing site to develop and manufacture vaccines, including its experimental COVID-19 shot, TNX-1800. The Montana facility intended to develop and manufacture Tonix's vaccine candidates will be a “public/private sector collaboration between Ravalli County and Tonix Pharmaceuticals that will bring more high-tech bioscience jobs to the Bitterroot Valley,” the company said.

Tonix Pharma Stock Moving Higher On Plans For Vaccine Manufacturing Facility In Bitterroot Valley

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC1).  Tonix plans to meet the FDA in Q3 of 2021 to seek agreement on designing a potential Phase 2 study and the overall clinical development plan.

Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome

Long COVID Symptoms of Pain, Sleep Disturbance, Fatigue and Brain Fog Overlap with Symptoms of Fibromyalgia, for which TNX-102 SL is in Mid-Phase 3 Development

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

CHATHAM, N.J., June 16, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m. ET.

Tonix Pharmaceuticals to Present at Raymond James Human Health Innovation Conference

News for Tonix Pharmaceuticals Hld Stock (TNXP)